Lumos Pharma Announces Topline Data From Phase 2 OraGrowtH210 And OraGrowtH212 Trials Of LUM-201 In PGHD Met All Primary And Secondary Endpoints
Portfolio Pulse from Benzinga Newsdesk
Lumos Pharma, Inc. (NASDAQ:LUMO) announced that its Phase 2 OraGrowtH210 and OraGrowtH212 trials of LUM-201 in pediatric growth hormone deficiency (PGHD) met all primary and secondary endpoints. The trials demonstrated that LUM-201 can enhance annualized height velocities (AHVs) in line with established standards for moderate PGHD patients undergoing recombinant growth hormone (rhGH) therapy. The company plans to discuss these data and finalize plans for a Phase 3 pivotal trial with the FDA in the first half of 2024.
November 07, 2023 | 10:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lumos Pharma's successful Phase 2 trials of LUM-201 in PGHD could position the company as a potential alternative to injectable therapies. This could have a positive impact on the company's stock in the short term.
The successful completion of Phase 2 trials and the potential to replace injectable therapies could lead to increased investor confidence in Lumos Pharma, potentially driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100